Camrelizumab plus apatinib CohortA

Phase 2Small molecule

Camrelizumab plus apatinib CohortA is one of 50 small molecule programs targeting Camrelizumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CamrelizumabRecruiting

Thyroid CancerActive, not recruiting

CamrelizumabPhase 2

Recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

20 2

Tafinlar

Novartis

Approved

11 3

Keytruda

Merck & Co.

Approved

9 4

Retevmo

Eli Lilly

Approved

3 5

Vitrakvi

Bayer

Approved

3 6

Nexavar

Bayer

Phase 3

12 7

Mekinist

Novartis

Phase 3

8 8

Gavreto

RRigel Pharmaceuticals

Approved

3 9

Alimta

SShawn Eagle

Approved

—10

Torisel

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Camrelizumab

NCT05139095

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Active, not recruiting·PPeking Union Medical College Hospital·Phase 2·NCT04560127·20 enrolled

Camrelizumab1 trial

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05139095·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Camrelizumab plus apatinib CohortA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camrelizumab plus apatinib CohortA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camrelizumab plus apatinib CohortA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking Union Medical College Hospital

Camrelizumab plus apatinib CohortA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Thyroid Cancer1 trial

Camrelizumab1 trial

References

Drug Info

Quick Facts

Related News